CYDY
CytoDyn Inc.Company Information
- Company Name
- CytoDyn Inc.
- CIK
- CIK0001175680
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CYDY: OTC
- Fiscal Year End
- May 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CYDY
SEC filing data through
Insider Sentiment
- Last purchase
- 2020-11-02
- Last sale
- 2020-12-22
- Shares purchased (TTM)
- 573,500
- Shares sold (TTM)
- 4,899,250
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 129,279
- Shares outstanding
- 1,289,302,000
- Ownership
- 0.01%
Earnings Market Reaction
- Filing date
- 2026-08-31
- Price on filing date
- —
- 1-month reaction
- -4.17%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-05-31 | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2025-02-28 | 2024-11-30 | 2024-08-31 | 2024-05-31 | 2024-02-29 | 2023-11-30 | 2023-08-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 12 | 16 | 5 | 9 | 12 | 16 | 21 | 25 | 3 | 1 | 0 | 2 | ||||||
| Prepaid Expense Current | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 3 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | 0 | - | - | - | 0 | 0 | 0 | 0 | 7 | 7 | 7 | 7 | ||||||
| Accounts And Other Receivables Net Current | 0 | - | - | - | 2 | 2 | 2 | 2 | - | - | - | - | ||||||
| Assets Current | 14 | 18 | 9 | 13 | 18 | 21 | 25 | 28 | 11 | 10 | 9 | 12 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 14 | 18 | 9 | 13 | 18 | 21 | 25 | 28 | 11 | 10 | 9 | 12 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 13 | 13 | 14 | 14 | 15 | 15 | 14 | 14 | 30 | 62 | 62 | 63 | ||||||
| Interest Payable Current | 11 | 12 | 15 | 17 | 18 | 19 | 18 | 16 | 15 | 14 | 13 | 12 | ||||||
| Dividends Payable Current | 10 | 9 | 9 | 9 | 8 | 8 | 8 | 7 | 7 | 6 | 6 | 6 | ||||||
| Convertible Debt Current | 1 | - | 27 | 27 | 27 | 27 | 29 | 29 | 30 | 30 | 33 | 33 | ||||||
| Derivative Liabilities Current | - | - | - | - | - | - | - | - | - | 3 | 0 | 4 | ||||||
| Liabilities Current | 54 | 50 | 85 | 69 | 71 | 71 | 71 | 70 | 84 | 129 | 123 | 129 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Convertible Debt Noncurrent | 26 | 27 | - | - | 0 | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | 44 | - | - | - | ||||||
| Liabilities | 124 | 123 | 129 | 113 | 114 | 114 | 114 | 113 | 128 | 130 | 124 | 129 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Treasury Stock Common Value | 0 | - | - | - | 0 | - | - | - | - | - | - | - | ||||||
| Additional Paid In Capital | 819 | 815 | 795 | 793 | 790 | 788 | 786 | 786 | 774 | 754 | 747 | 735 | ||||||
| Retained Earnings Accumulated Deficit | -930 | -921 | -916 | -893 | -888 | -882 | -877 | -872 | -892 | -875 | -863 | -853 | ||||||
| Stockholders Equity | -110 | -104 | -120 | -100 | -96 | -93 | -89 | -85 | -117 | -119 | -114 | -117 | ||||||
| Liabilities And Stockholders Equity | 14 | 18 | 9 | 13 | 18 | 21 | 25 | 28 | 11 | 10 | 9 | 12 | ||||||
| Series B Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Series C Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Series D Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 2,250 | 2,250 | 2,250 | 1,750 | 2,250 | 1,750 | 1,750 | 1,750 | 1,750 | 1,750 | 1,750 | 1,350 | ||||||
| Common Stock Shares Issued | 1,374 | 1,358 | 1,266 | 1,257 | 1,249 | 1,233 | 1,224 | 1,220 | 1,059 | 990 | 972 | 931 | ||||||
| Shares Outstanding | 1,374 | 1,358 | 1,266 | 1,257 | 1,249 | 1,232 | 1,223 | 1,220 | 1,059 | 990 | 971 | 931 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCytoDyn Inc. (CYDY) — SEC Financial Statements & Analysis
CytoDyn Inc. (CYDY) is a pharmaceutical preparations company, incorporated in DE. CytoDyn Inc. trades on OTC as: CYDY. CytoDyn Inc. (CYDY)'s most recent SEC filing is a Form 10-K for the period ended 2026-05-31, filed with the SEC on 2026-08-31. Based on its latest SEC filing (Form 10-Q, period ending 2026-05-31), CytoDyn Inc. carries a market cap of $386.79M, a P/E ratio of -9.06x, a P/B ratio of -3.53x, an enterprise value of $402.14M, and an EV/EBITDA multiple of -10.43x. On profitability, it posts a Return on Equity (ROE) of 41.50% and a Return on Assets (ROA) of -266.70%. Per share, it reports EPS of $-0.03, diluted EPS of $-0.03, free cash flow per share of $-0.01, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -1240.16% year-over-year, and EPS growth of -1166.28% year-over-year. On the balance sheet, it maintains a current ratio of 0.26x, a quick ratio of 0.24x, working capital of $-39.85M, a debt-to-equity ratio of -1.13x, a debt ratio of 8.85, an interest coverage ratio of 0.80x, free cash flow of $-17.25M (TTM), and net debt of $15.35M. Figures sourced from SEC EDGAR.
- Market Cap
- $386.79M
- P/E TTM
- -9.06x
- EPS TTM
- $-0.03
- P/B TTM
- -3.53x
- ROE TTM
- 41.50%
- ROA TTM
- -266.70%
- Debt To Equity
- -1.13x
- Free Cash Flow TTM
- $-17.25M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-05-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CytoDyn Inc. in?
CytoDyn Inc. (CYDY) operates in the Pharmaceutical Preparations industry.
What exchange does CYDY trade on?
CytoDyn Inc. (CYDY) trades on the OTC.
Where is CytoDyn Inc. incorporated?
CytoDyn Inc. is incorporated in DE.
When was CytoDyn Inc. (CYDY)'s most recent SEC filing?
CytoDyn Inc. (CYDY)'s most recent SEC filing is a Form 10-K for the period ended 2026-05-31, filed with the SEC on 2026-08-31.
What is CYDY's market cap?
CytoDyn Inc. (CYDY) has a market capitalization of $386.79M as of 2026-05-31.
What is CYDY's EPS (earnings per share)?
CytoDyn Inc. (CYDY)'s trailing twelve month EPS is $-0.03 as of 2026-05-31.
What is CYDY's ROE (return on equity)?
CytoDyn Inc. (CYDY)'s trailing twelve month Return on Equity (ROE) is 41.50% as of 2026-05-31.
What is CYDY's ROA (return on assets)?
CytoDyn Inc. (CYDY)'s trailing twelve month Return on Assets (ROA) is -266.70% as of 2026-05-31.
What is CYDY's EV/EBITDA?
CytoDyn Inc. (CYDY)'s trailing twelve month EV/EBITDA is -10.43x as of 2026-05-31.